When the market gets louder, the details matter more.
Novo and Lilly are now fighting over advertising claims, pill data are changing the long-term GLP-1 conversation, and women's hormone care has a new licensed option.
The GLP-1 rivalry got sharper this week. Novo Nordisk has sued Eli Lilly over weight-loss advertising claims it says are misleading, just as new trial data suggest a daily GLP-1 pill could help some people maintain weight loss after injectable treatment.
For readers comparing providers, the useful lesson is not that one brand always beats another. It is that dose, trial design, route of administration and follow-up support all change the picture. Away from weight loss, the UK has also approved its first testosterone cream formulated specifically for postmenopausal women, although access is expected to begin privately.
In this round-up
Novo Nordisk sues Eli Lilly over weight-loss drug advertising claims
Novo Nordisk has filed a lawsuit against Eli Lilly in federal court in New Jersey, accusing its rival of running advertising that makes Zepbound and Mounjaro look more effective than Novo believes the evidence supports.
The dispute centres on how the drugs are compared. Novo argues that Lilly has promoted comparisons using the highest approved doses of its own drugs against lower doses of Wegovy and Ozempic, while leaving out newer higher-dose Wegovy data that Novo says would narrow the apparent gap.
It is a commercial fight, but it matters for patients because these headline claims often filter into provider pages, ads and social content. A percentage can look definitive until you check the dose, population, endpoint and source behind it.
Treat "our drug beats theirs" claims as marketing unless the comparison is dose-matched and based on comparable trial data. If you are comparing Mounjaro and Wegovy, look at the specific dose, side-effect profile, price and clinical support rather than a single headline result.
Orforglipron data raise the question of GLP-1 maintenance after injections
Results from Lilly's Phase 3 ATTAIN-MAINTAIN trial suggest the oral GLP-1 orforglipron helped people maintain more of their earlier weight loss after switching from injectable incretin treatment than placebo did.
The study followed people who had previously lost weight on injectable treatments such as tirzepatide or semaglutide, then switched to either orforglipron or placebo. The practical question is familiar: what happens after the first phase of weight loss, and can a tablet become part of a longer-term maintenance plan?
If you are using Wegovy or Mounjaro and thinking about stopping, do not treat this as a reason to make changes now. Orforglipron is not a UK-approved weight-loss option yet. The useful takeaway is to plan stopping or switching with a prescriber, rather than assuming treatment can simply end once the first target is reached.
AndroFeme becomes the first testosterone cream licensed for UK women
AndroFeme, a testosterone cream formulated for women, has received UK marketing authorisation from the MHRA. The product is expected to become available in the UK during 2026 and is licensed for hypoactive sexual desire disorder in postmenopausal women where HRT alone has not helped.
Until now, women prescribed testosterone in the UK have often used products originally licensed and dosed for men, with clinicians adjusting the amount used. A women-specific licensed product should make prescribing and dosing clearer, although NHS availability has not been confirmed.
This is an access and formulation change, not a reason to self-treat. Testosterone is prescription-only and suitability depends on symptoms, medical history, current HRT, blood results and specialist advice. Expect private access first unless NHS inclusion follows later.
GLP-1 pricing: what is actually moving
- Wegovy injections remain a lower entry point at several providers, but maintenance-dose pricing is still where the larger monthly difference appears.
- Discount codes are especially volatile in weight loss. First-month offers can make a provider look cheaper than it will be at dose escalation or renewal.
- Mounjaro remains the more expensive route at many UK providers after wholesale price movement, although individual checkout prices vary by dose and offer.
- Oral GLP-1s are becoming a separate comparison market. The useful comparison is no longer only Wegovy versus Mounjaro, but injection versus tablet, starter dose versus maintenance dose, and support included versus medicine-only pricing.
Beyond weight loss: TRT, hair loss and blood testing
- TRT awareness continues to grow, but the safest providers still require proper blood testing, clinical assessment and follow-up rather than questionnaire-only prescribing.
- Hair loss pipeline news is moving slowly, with finasteride and minoxidil still the established medical options most readers will see in current provider comparisons.
- At-home blood testing keeps expanding as providers try to reduce friction around venous draws and repeat monitoring. The practical comparison is sample quality, markers included and follow-up explanation, not only the kit price.
Market and investment signals
- Numan has continued to position itself as a broader preventative-health platform, with recent funding aimed at women's health expansion and AI-supported coaching.
- Women's health policy remains a growth area, with government attention on digital access, FemTech and service models that reduce fragmented care.
- Provider positioning is likely to become more evidence-led as GLP-1 advertising claims attract legal and regulatory scrutiny.
Medical disclaimer
This article is for general information only and is not medical advice. Prescription medicines, including GLP-1 treatments and testosterone, require assessment by a qualified healthcare professional. Do not start, stop or switch treatment based on a news article.
Sources
- Novo Nordisk sues Eli Lilly over GLP-1 drug ads, STAT News
- Lilly's orforglipron maintenance trial announcement, Eli Lilly
- Testosterone cream now licensed for UK women, Dr Louise Newson
- MHRA approves testosterone cream for UK postmenopausal women, Lawley Pharmaceuticals
- Boots Online Doctor launches oral Wegovy, Boots UK
- Numan secures $60M, Numan
- Women's voices to be at the heart of renewed health strategy, GOV.UK
- NHSE explores home testing via NHS App, Digital Health
